ResearcherThe University of SydneyActive in the last 2 years
Sooin Byeon
Matched on OpenAlex author ID A5033747018. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2023: 1 paper · 2024: 2 papers · 2025: 3 papers
Papers 6
- FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. Co-author DOI 10.1002/cam4.70500↗
- Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. First author DOI 10.1111/eci.14341↗
- Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery. Co-author DOI 10.1111/eci.70046↗
- Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. Co-author DOI 10.1002/ijc.34928↗
- Serum and tissue metallome of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16124↗
- Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single-cell analysis. Co-author DOI 10.1002/cam4.6407↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jaswinder Singh Samra · 6 shared papers, 2023–2025 · strength 1.38
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500↗
- Paper Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuva… DOI 10.1111/eci.70046↗
- Paper Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. DOI 10.1002/ijc.34928↗
- Anthony James Gill · 6 shared papers, 2023–2025 · strength 1.38
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500↗
- Paper Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuva… DOI 10.1111/eci.70046↗
- Paper Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. DOI 10.1002/ijc.34928↗
- Sumit Sahni · 6 shared papers, 2023–2025 · strength 1.38
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500↗
- Paper Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuva… DOI 10.1111/eci.70046↗
- Paper Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. DOI 10.1002/ijc.34928↗
- Anubhav Mittal · 6 shared papers, 2023–2025 · strength 1.38
- Paper FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. DOI 10.1002/cam4.70500↗
- Paper Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuva… DOI 10.1111/eci.70046↗
- Paper Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. DOI 10.1002/ijc.34928↗
- Sarah Maloney · 3 shared papers, 2024–2025 · strength 0.69
- Paper Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuva… DOI 10.1111/eci.70046↗
- Paper Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. DOI 10.1111/eci.14341↗
- Paper Serum and tissue metallome of pancreatic ductal adenocarcinoma. DOI 10.1111/cas.16124↗
- Angela S. Y. Chou · 2 shared papers, 2025 · strength 0.48
- Josef Gillson · 2 shared papers, 2023–2025 · strength 0.43
- Taymin du Toit‐Thompson · 2 shared papers, 2023–2024 · strength 0.42
- Nathalie B. Rasko · 1 shared paper, 2025 · strength 0.25
- Christopher Bahdah Nahm · 1 shared paper, 2025 · strength 0.25
- Mark P. Molloy · 1 shared paper, 2024 · strength 0.24
- Stephen John Clarke · 1 shared paper, 2025 · strength 0.23
- Nick Pavlakis · 1 shared paper, 2025 · strength 0.23
- David Lok Hang Chan · 1 shared paper, 2025 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.